Journal
CLINICAL JOURNAL OF ONCOLOGY NURSING
Volume 21, Issue 1, Pages 121-122Publisher
ONCOLOGY NURSING SOC
DOI: 10.1188/17.CJON.121-122
Keywords
pegfilgrastim; febrile neutropenia; patient satisfaction; on-body injector
Ask authors/readers for more resources
Many chemotherapy regimens used today require the support of a granulocyte-colony-stimulating factor for the prevention of life-threatening neutropenia. In March 2015, a delivery method was introduced for Neulasta (R) (pegfilgrastim) through an on-body injector (Onpro (R)), which may eliminate the need for patients to return for injection after chemotherapy, increase workflow, and allow more patients to be seen. The purpose of this study was to monitor the implementation of the Onpro delivery system in an outpatient facility.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available